IP Group appoints former 3i chief as incoming chair
IP Group PLC (LSE:IPO), the LSE-listed science and technology investor, has appointed Michael Queen as non-executive director and chair designate, concluding a succession process announced last year. Queen will take over as chair following the company's annual general meeting on 18 June 2026, when Sir Douglas Flint retires from the board after nearly eight years of service.
IP Group investee company First Light Fusion raises £25m in fusion energy push
First Light Fusion, an IP Group PLC (LSE:IPO) portfolio company developing inertial fusion energy technology, has raised £25 million in the first close of a new funding round led by specialist fusion fund Starmaker One and backed by the UK Atomic Energy Authority (UKAEA). The round was led by East X Ventures, a UK venture firm, through its Starmaker One fusion fund, with a significant strategic investment from the UKAEA, the government body responsible for leading the UK's fusion energy programme.
IP Group launches Australian cleantech fund with clean energy body
IP Group PLC (LSE:IPO), the LSE-listed science and technology investor, has launched a new fund with Australia's Clean Energy Finance Corporation (CEFC) to back cleantech companies targeting hard-to-abate industries. The IP Group Climate Catalyst Fund has a target size of up to A$150 million, with IP Group contributing A$30 million and the CEFC A$20 million as cornerstone investors at first close.
Here's why IP Group looks undervalued. Three brokers take a deep dive
Analysts at three brokerages maintain 'buy' ratings after strong full-year results IP Group PLC (LSE:IPO), the London-listed investor that commercialises intellectual property from leading universities, reported a 13% rise in net asset value (NAV) per share to 110.4p for the year ended December 2025, driven by a licensing deal tied to Pfizer's $10 billion acquisition of obesity drug developer Metsera. The company's shares rose 11% on Tuesday to 54.7p.
IP Group portfolio company Oxa raises $103 million in Series D backed by National Wealth Fund and Nvidia
IP Group PLC (LSE:IPO), the London-listed science and technology investor, said portfolio company Oxa Autonomy has raised $103 million in the first close of a Series D funding round, backed by the UK's National Wealth Fund and NVentures, the venture capital arm of chip designer Nvidia. IP Group invested £7.5 million from its own balance sheet and a further £19 million through funds it manages on behalf of Australian pension fund Hostplus, giving it a combined beneficial holding of 20.3% in Oxa.
Chart Of The Day: With Past IPOs Slumping, Will Mega-Deals Proceed?
This could be the year of the mega-IPO - with top Artificial Intelligence (AI) companies and SpaceX eyeing 2026 public market debuts. But the performance of past IPOs is souring, raising questions about investor enthusiasm for big deals. The MoneyShow Chart of the Day shows the performance of the Renaissance IPO Index and the S&P 500 Index over the past year. The IPO index generally tracked, or even outperformed, the S&P until September. But it has notably underperformed since then.
IP Group portfolio company Microbiotica reports promising trial results in ulcerative colitis
MB310, a live biotherapeutic developed by Cambridge-based Microbiotica, achieves 63% remission rate in early study IP Group PLC (LSE:IPO), the London-listed investor in science and technology companies, has announced that portfolio company Microbiotica has reported positive results from a Phase 1b trial of its lead microbiome medicine in ulcerative colitis. The trial met its primary and secondary endpoints, with MB310 demonstrating a strong safety profile, robust engraftment of its eight-strain bacterial consortium and statistically significant clinical improvements compared with placebo.
From OpenAI To SpaceX: The IPO ETF Bet On A 2026 Go-Public Surge
Renaissance IPO ETF (IPO) is rated a buy, anticipating a surge in major IPOs through 2026 to fuel renewed investor interest. IPO's portfolio is heavily growth-oriented, with 94% SMID-cap exposure and a 42% weighting in Information Technology. Despite a high 26.9x P/E, IPO's long-term earnings growth near 32% yields a compelling PEG ratio below 2.
IP Group hails $115m fundraising at Artios as cancer-drug developer accelerates late-stage trials
IP Group PLC (LSE:IPO) has welcomed a major funding milestone at its portfolio company Artios Pharma, after the DNA-damage-response specialist closed an oversubscribed $115 million Series D round that will push two of its most advanced cancer programmes deeper into clinical development. Cambridge-based Artios is developing treatments that target weaknesses in the way cancer cells repair their DNA, a field known as DDR.
IP Group's investments are paying off - ICYMI
IP Group PLC (LSE:IPO) CEO Greg Smith joined Proactive to discuss the company's strategic outlook, recent exits, and high-potential investments. Topics include future royalty streams from obesity drug programs, portfolio realisations, and IP Group's backing of clean tech innovator OXCCU.
IP Group scores another exit as CoreWeave moves to buy Monolith
IP Group PLC (LSE:IPO) has announced that one of its portfolio companies, Monolith, is being acquired by Nasdaq-listed CoreWeave, marking another successful sale from its deeptech investments. The London-listed investment firm, which holds a 12.3% stake in Monolith, said the deal follows recent disposals of other portfolio businesses, Featurespace and Garrison.
IP Group: OXCCU raises £20m to advance sustainable aviation fuel tech
IP Group PLC (LSE:IPO) portfolio company OXCCU has raised £20.75 million in an oversubscribed Series B funding round. The Oxford University spin-out is developing a single-step process to convert waste carbon into sustainable aviation fuel.
